Plan African market entry and trial strategy with better evidence.

Kapsule helps pharma teams understand burden, patient availability, and market opportunity across African countries before committing budget.

Which markets have the patient depth and site readiness for your next study?

8
Countries assessed
4
Priority markets
122
Qualified sites
200K+
Eligible patients
Country comparison
Diagnostic capacity
Patient depth
Market
Dx capacity
Patients
Sites
Signal
South Africa
Dx capacity
48
Patients6.2K
Sites31
Signal
Ready
Kenya
Dx capacity
34
Patients8.1K
Sites28
Signal
Ready
Nigeria
Dx capacity
18
Patients14.8K
Sites36
Signal
Explore
Ghana
Dx capacity
14
Patients3.2K
Sites14
Signal
Explore
Decision output

South Africa leads on diagnostic infrastructure; Nigeria has the largest patient pool but lower per-capita capacity. Kenya balances both. Recommended for Phase III feasibility.

Next step: validate site-level infrastructure in SA and Kenya; scope patient recruitment strategy for Nigeria.

Questions Kapsule can help you answer

Kapsule is most useful when teams need a faster, more evidence-based way to make African market decisions.

  • Which countries should we prioritize for a therapy area, and what evidence supports that choice?
  • How large and accessible are relevant patient populations across target markets?
  • Where do trial feasibility and commercial opportunity overlap most clearly?
  • How do we reduce time spent stitching together fragmented local market inputs?

How Kapsule helps

Each workflow is designed to turn fragmented local inputs into clearer decisions.

Market sizing

Compare burden, demand, and care patterns across countries before committing commercial resources.

  • Country-by-country opportunity scans
  • Disease-burden comparisons
  • Shortlists for launch planning

Trial feasibility

Estimate patient depth and likely site potential earlier in the planning cycle.

  • Patient population signals
  • Facility and network context
  • Earlier go or no-go inputs

Portfolio planning

Support strategy, market access, and business-development teams with one Africa-focused intelligence layer.

  • Cross-functional decision support
  • Market-entry briefing inputs
  • Evidence for internal prioritization

Why teams choose Kapsule

The difference is not just data access. It is Africa-specific context that helps teams act faster.

  • Africa-specific data infrastructure rather than a generic global overlay
  • Patient and market intelligence in one workflow
  • Useful for strategy, medical, access, and business-development teams
  • A practical guide to African trial planning and feasibility

See which African markets are worth prioritizing next.

Start with the guide, then talk to the team if you want to explore a specific trial or feasibility question.